Prevenar 13 is indicated for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae. The dose in children aged 5–17 years is 0.5ml by intramuscular injection, preferably into the deltoid muscle of the upper arm.
In an open-label study (n=592), a single dose of Prevenar 13 was given to children aged 5–10 years who had received at least one previous dose of Prevenar (7-valent) and to children aged 10–17 years who had never received a pneumococcal vaccine.
IgG response non-inferior to four-dose course in younger children
In all patients, the immune response to all 13 serotypes, as measured by serum IgG, was non-inferior to that observed in infants who received a four-dose course of Prevenar 13. In addition, functional antibody geometric mean titres one month following vaccination in children aged 10–17 years were non-inferior to those observed in the 5–10 year age group for 12 of the 13 serotypes (except serotype 3).
View Prevenar 13 drug record
Further information: Pfizer Ltd